Acumen research and consulting estimates that the global sepsis diagnostics market is anticipated to reach market size of around US$ 800 Mn by 2027 and is anticipated to grow at a CAGR of around 9% in terms of revenue during the forecast period 2020 – 2027. Sepsis is a serious complication due to an impaired immune system that leads to bacterial, viral, fungal, parasitic or other infection. In hospitals, sepsis is a major cause of death. Sepsis occurs if the body's immune system responds to a disease and chemicals are released to treat the infection through the immune system. It also causes inflammation in the body when it enters the bloodstream. It leads to blood clots, blood vessel leakage, and poor blood flow, and oxygen and nutrients have been taken away from the vital bodies. Many physicians starting with sepsis and leading to severe sepsis, and ultimately to a septic shock, which is considered a medical emergency, are considered as a three-stage syndrome.
The growing prevalence of various antibiotic resistant bacterial strains, aging individuals, and increasing awareness of health and healthcare expenses is key to the growth of the global market for sepsis diagnosis. Moreover, the growth of the global sepsis diagnostics market will in the near future be driven by the increasing number of surgical procedures and by an increase in the number of product approvals. The major factor in the growth of the global sepsis diagnostics market is the high incidence of infected hospitals. According to Centers for Disease Control and Prevention (CDC), in the U.S. over 1.7 million adults suffer from sepsis every year, which leads to approximately 270,000 deaths. In addition, according to the 2018 Organization for Economic Co-operation and Development (OECD) report, approximately 3.8 million patients in acute care hospitals in European countries suffer from hospital-acquiring infections (HAIs) every year. The high prevalence of healthcare-associated infections (HAIs) in key regions is expected to increase medical testing solutions demand significantly and therefore fuel market growth during the forecast period.
In 2019, the microbiology segment accounts to hold large market share of global sepsis diagnostics market and is projected to grow the market during forecast period 2020-2027. It can be mentioned even though microbiology enables microorganisms through the use of media for blood culture to be quantitatively identified through blood culture testing. A profitable CAGR over the forecast period is expected to be seen in the molecular diagnosis segment. Due to its various benefits, such as high sensitivity, accuracy, and less turnaround time over other technologies, increasing use of molecular diagnostic technology will drive the growth of the segment. However, it is an inconvenience to this technique that uncultivable organisms are not identified. However, molecular diagnostic technique is regarded after blood cultivation as a normal pathogen identification technique.
The market research study on “Sepsis Diagnostics Market (By Technology: Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry; By Product: Blood Culture Media, Instruments, Assays & Reagents; By Method: Conventional Diagnostics, Automated Diagnostics; By Usability: Laboratory Testing, Point-of-care Testing; By Pathogen: Bacterial Sepsis, Gram-negative Bacterial Sepsis, Gram-positive Bacterial Sepsis, Fungal Sepsis, Others) - Global Industry, Analysis, Market Size, Opportunities and Forecast, 2020 - 2027” offers detailed insights on the global sepsis diagnostics market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report also provides competitive landscape to understand the current stance of particular player. The report provides insights on global sepsis diagnostics market are technology, product, method, usability, pathogen and major geographic regions. The sepsis diagnostics market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. For each region, the market size for different segments has been covered under the scope of report.
North America accounts to hold large market share of global sepsis diagnostics market in 2019 due to Due to factors such as increased demand of better health care facilities, increasing adoption of new and advanced diagnostic techniques, high per capita health expenditure and increased incidences of chronic diseases such as cancer, diabetes, and others. In terms of factors such as increasing geriatric population in the region combined with developing healthcare facilities and an increase in cancer and diabetes prevalence in countries like India , China and Australia, the Asia Pacific region is expected to be at their highest level during the forecast period 2020-2027. However, in Asia Pacific some factors restrict sepsis diagnostic market growth in this region are lacking awareness and skilled workers.
Major players included in this report are Roche Diagnostics, Becton Dickinson Company, bioMérieux, Danaher, Bruker, Abbott Laboratories, T2 Biosystems, Luminex, Thermo Fisher Scientific, EKF Diagnostics, Response Biomedica, Immunexpress, Axis-Shield Diagnostics, CytoSorbents, and others.
The global sepsis diagnostics market is segmented as below:
Sepsis Diagnostics Market By Technology
Sepsis Diagnostics Market By Product
Blood Culture Media
Assays & Reagents
Sepsis Diagnostics Market By Usability
Sepsis Diagnostics Market By Pathogen
Gram-negative Bacterial Sepsis
Gram-positive Bacterial Sepsis
Sepsis Diagnostics Market By Geography
Middle East & Africa
Rise in cases of hospital-acquired infections is expected to drive the growth of the sepsis diagnostics market.
The market value of sepsis diagnostics is anticipated to be around US$ 800 Mn in 2027.
It is anticipated to grow around 9% CAGR amid the forecast period.2020-2027
The key players operating in sepsis diagnostics market such as Roche Diagnostics, Becton Dickinson Company, bioMérieux, Danaher, Bruker, Abbott Laboratories, T2 Biosystems, Luminex, Thermo Fisher Scientific, EKF Diagnostics, Response Biomedica, Immunexpress, Axis-Shield Diagnostics, CytoSorbents, and others.
Asia Pacific is projected to grow at a fast pace during forecast period from 2020-2027.
North America held maximum share in 2019.
Absence of standard protocol is a major factor expected to restraint the growth of the market.